Spanish 
Dutch 
French 
German 
Norwegian Bokmål 
Polish 
Swedish
On Thursday, May 8, Quirónsalud Torrevieja Hospital will convene over 100 medical specialists to explore the latest advances in the diagnosis and treatment of pancreatic cancer—one of the most complex and challenging diseases in oncology due to its typically late diagnosis and aggressive progression.
Pancreatic cancer often develops silently, with few or no symptoms in its early stages, making early detection particularly difficult. When diagnosed early and the tumor remains localized, surgery continues to be the most effective treatment for curative purposes. In such cases, the tumor has not yet invaded surrounding tissue or metastasized to other parts of the body.
A major focus of the event will be the evolution of surgical oncology, particularly the growing role of robotic surgery. This technology represents a significant breakthrough in pancreatic cancer treatment, offering millimeter-level precision, enhanced 3D visualization, and superior instrument control. These advantages translate into reduced blood loss, less postoperative pain, and faster recovery times—ultimately allowing patients to begin follow-up treatments like chemotherapy or radiotherapy sooner.
The symposium, held at Quirónsalud Torrevieja, will be led by Dr. Pedro Bretcha, Head of the General Surgery and Surgical Oncology Department at the hospital. The gathering is part of a series of events celebrating the hospital’s 25th anniversary. Additional information and registration details are available on the Quirónsalud website.
Commitment to Healthcare Excellence in the Region
Quirónsalud has a strong presence in the Valencian Community and the Region of Murcia, where it operates numerous medical centers equipped with state-of-the-art technology. It is a leading name in private healthcare, recognized for both the quality of patient care and the professional environment it offers to its medical teams.
As Spain’s largest healthcare group—and a major player in Europe through its parent company, Fresenius-Helios—Quirónsalud operates over 180 medical centers worldwide, including 57 hospitals with more than 8,000 beds. The group employs over 50,000 healthcare professionals and is active in Spain, Latin America, and beyond.
Prominent centers within the network include the Jiménez Díaz Foundation University Hospital, Teknon Medical Center, Ruber International, and Quirónsalud hospitals in Madrid, Barcelona, and Seville. Ten of its hospitals are university-affiliated, reflecting the group’s strong emphasis on teaching and research. Its FJD Health Research Institute is nationally accredited and actively involved in groundbreaking research across multiple specialties, including oncology, cardiology, endocrinology, gynecology, and neurology.
With a model built on integrated healthcare services, Quirónsalud leverages its broad network to translate clinical research into real-world treatments—ensuring that innovation benefits patients across all its centers.
Spanish Dutch French German Norwegian Bokmål Polish Swedish
